Mesoblast Stock Fundamentals
| MESO Stock | USD 13.55 0.27 2.03% |
Mesoblast fundamentals help investors to digest information that contributes to Mesoblast's financial success or failures. It also enables traders to predict the movement of Mesoblast Stock. The fundamental analysis module provides a way to measure Mesoblast's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Mesoblast stock.
At this time, Mesoblast's Interest Expense is very stable compared to the past year. As of the 15th of March 2025, Research Development is likely to grow to about 37.9 M, while Depreciation And Amortization is likely to drop about 1.8 M. Mesoblast | Select Account or Indicator |
Mesoblast Company Return On Asset Analysis
Mesoblast's Return on Asset or ROA shows how effective is the management of the company in generating income from utilizing all of the assets at their disposal. It is a useful ratio to evaluate the performance of different departments of a company as well as to understand management performance over time.
Current Mesoblast Return On Asset | -0.0541 |
Most of Mesoblast's fundamental indicators, such as Return On Asset, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Mesoblast is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Return on Asset measures overall efficiency of a company in generating profits from its total assets. It is expressed as the percentage of profits earned per dollar of Asset. A low ROA typically means that a company is asset-intensive and therefore will needs more money to continue generating revenue in the future.
| Competition |
Mesoblast Total Assets
Total Assets |
|
Based on the latest financial disclosure, Mesoblast has a Return On Asset of -0.0541. This is 99.38% lower than that of the Biotechnology sector and 99.77% lower than that of the Health Care industry. The return on asset for all United States stocks is 61.36% lower than that of the firm.
Mesoblast Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Mesoblast's current stock value. Our valuation model uses many indicators to compare Mesoblast value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Mesoblast competition to find correlations between indicators driving Mesoblast's intrinsic value. More Info.Mesoblast is considered to be number one stock in return on equity category among its peers. It is regarded second in return on asset category among its peers . At this time, Mesoblast's Return On Equity is very stable compared to the past year. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Mesoblast's earnings, one of the primary drivers of an investment's value.Mesoblast Return On Asset Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Mesoblast's direct or indirect competition against its Return On Asset to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Mesoblast could also be used in its relative valuation, which is a method of valuing Mesoblast by comparing valuation metrics of similar companies.Mesoblast is currently under evaluation in return on asset category among its peers.
Mesoblast Current Valuation Drivers
We derive many important indicators used in calculating different scores of Mesoblast from analyzing Mesoblast's financial statements. These drivers represent accounts that assess Mesoblast's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Mesoblast's important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Market Cap | 852.9M | 259.0M | 531.2M | 657.9M | 756.6M | 1.3B | |
| Enterprise Value | 821.5M | 305.8M | 576.8M | 714.3M | 821.4M | 1.2B |
Mesoblast ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Mesoblast's sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Mesoblast's managers, analysts, and investors.Environmental | Governance | Social |
Mesoblast Fundamentals
| Return On Equity | -0.18 | ||||
| Return On Asset | -0.0541 | ||||
| Operating Margin | (12.49) % | ||||
| Current Valuation | 1.75 B | ||||
| Shares Outstanding | 114.18 M | ||||
| Shares Owned By Insiders | 0.07 % | ||||
| Shares Owned By Institutions | 1.38 % | ||||
| Number Of Shares Shorted | 2.26 M | ||||
| Price To Earning | (5.90) X | ||||
| Price To Book | 3.66 X | ||||
| Price To Sales | 297.45 X | ||||
| Revenue | 5.9 M | ||||
| Gross Profit | (47.42 M) | ||||
| EBITDA | (56.08 M) | ||||
| Net Income | (87.96 M) | ||||
| Cash And Equivalents | 85.5 M | ||||
| Cash Per Share | 0.62 X | ||||
| Total Debt | 118.92 M | ||||
| Debt To Equity | 0.21 % | ||||
| Current Ratio | 1.90 X | ||||
| Book Value Per Share | 0.42 X | ||||
| Cash Flow From Operations | (48.46 M) | ||||
| Short Ratio | 6.69 X | ||||
| Earnings Per Share | (1.05) X | ||||
| Target Price | 14.5 | ||||
| Number Of Employees | 73 | ||||
| Beta | 2.34 | ||||
| Market Capitalization | 1.14 B | ||||
| Total Asset | 669.15 M | ||||
| Retained Earnings | (908.76 M) | ||||
| Working Capital | 13.22 M | ||||
| Current Asset | 88.82 M | ||||
| Current Liabilities | 29.41 M | ||||
| Net Asset | 669.15 M |
About Mesoblast Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Mesoblast's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Mesoblast using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Mesoblast based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.| Last Reported | Projected for Next Year | ||
| Current Deferred Revenue | 5.8 M | 8.8 M | |
| Total Revenue | 6.8 M | 6.4 M | |
| Cost Of Revenue | 47.2 M | 38.1 M | |
| Stock Based Compensation To Revenue | 1.14 | 1.09 | |
| Sales General And Administrative To Revenue | 4.60 | 4.37 | |
| Research And Ddevelopement To Revenue | 4.94 | 4.69 | |
| Capex To Revenue | 0.06 | 0.06 | |
| Revenue Per Share | 0.01 | 0.01 | |
| Ebit Per Revenue | (12.83) | (13.47) |
Check out Mesoblast Piotroski F Score and Mesoblast Altman Z Score analysis. To learn how to invest in Mesoblast Stock, please use our How to Invest in Mesoblast guide.You can also try the Portfolio Volatility module to check portfolio volatility and analyze historical return density to properly model market risk.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Mesoblast. If investors know Mesoblast will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Mesoblast listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (1.05) | Revenue Per Share | Quarterly Revenue Growth (0.41) | Return On Assets | Return On Equity |
The market value of Mesoblast is measured differently than its book value, which is the value of Mesoblast that is recorded on the company's balance sheet. Investors also form their own opinion of Mesoblast's value that differs from its market value or its book value, called intrinsic value, which is Mesoblast's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Mesoblast's market value can be influenced by many factors that don't directly affect Mesoblast's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Mesoblast's value and its price as these two are different measures arrived at by different means. Investors typically determine if Mesoblast is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Mesoblast's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.